Biomedical Engineering Reference
In-Depth Information
H
3
C
CH
3
O
O
O
H
N
N
N
N
H
S
N
N
H
N
H
O
N
O
NH
2
OH
N
O
OH
S
CH
3
H
3
C
O
H
O
CH
3
CH
3
H
3
C
CH
3
SO
2
OH
CH
3
Saquinavir
Ritonavir
CH
3
H
3
C
CH
3
N
OH
O
NH
S
N
CH
3
O
N
N
CH
3
SO
2
OH
HO
N
O
H
O
H
HO
OH
H
3
C
CH
3
CH
3
Indinavir
Nelinavir
NH
2
CH
3
OH
O
O
O
H
N
O
O
N
NH
S
N
H
O
O
CH
3
N
N
H
O
O
OH
CH
3
H
3
C
CH
3
CH
3
Amprenavir
Lopinavir
N
O
OO
O
S
O
N
H
N
O
OH
O
N
N
O
CH
3
N
O
O
NH
2
O
H
H
P
OH
HO
CH
3
O
O
Atazanavir
Fosamprenavir
O
O
OO
N
H
O
O
S
O
O
N
H
OH
N
F
HO
O
S
F
F
O
NH
2
Tipranavir
Darunavir
FIGURE 24.6
Structures of a number of HIV protease inhibitors (PIs).
Principal indication(s)
: HIV infection, in combination with other anti-HIV agents (particularly PIs
to boost their anti-HIV activity).
Administered
: Orally at 1200 mg/day (six 100 mg capsules, twice a day to be taken with food), or if
used as “booster” for other PIs, at 100 mg twice daily.
